Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies

Colloids and Surfaces B: Biointerfaces

Volumn 123, Issue , 2014, Pages 610-615

  Negi, Lalit Mohan ^a   Talegaonkar, Sushama ^a   Jaggi, Manu ^b   Verma, Anita Kamra ^c   Verma, Ritu ^b   Dobhal, Sheetal ^b   Kumar, Vijay ^c  

^a HAMDARD UNIVERSITY   (India)

^b DABUR RESEARCH FOUNDATION   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

Ehrlich's ascites tumor; Hyaluronic acid; Irinotecan; NLC; Tumor targeting

Indexed keywords

BIOCOMPATIBILITY; CONTROLLED DRUG DELIVERY; HISTOLOGY; ORGANIC ACIDS; PHARMACODYNAMICS; RADIATION; RADIOACTIVITY; TARGETED DRUG DELIVERY; TUMORS;

ANTI-CANCER DRUG DELIVERY; BIODISTRIBUTIONS; DELIVERY SYSTEMS; EFFECTIVE MANAGEMENT; IRINOTECAN; NANOSTRUCTURED LIPID CARRIERS; THROMBOCYTOPENIA; TUMOR TARGETING;

HYALURONIC ACID;

HERMES ANTIGEN; HYALURONIC ACID; IRINOTECAN; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG COATING; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG TISSUE LEVEL; DRUG UPTAKE; EHRLICH ASCITES TUMOR; HEMOLYSIS; IN VIVO STUDY; MACROPHAGE; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIDRUG RESISTANCE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PROTEIN INTERACTION; RADIOACTIVITY; SURFACE PROPERTY; THROMBOCYTOPENIA;

EID: 84915752375     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.09.061     Document Type: Article

References (29)

1. Sosnik A. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing generally recognized as safe (GRAS) nanopharmaceuticals: a review. Adv. Drug Deliv. Rev. 2013, 65:1828-1851.
2. Bansal T., Akhtar N., Jaggi M., Khar R.K., Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov. Today 2009, 14:1067-1074.
3. Akhtar N., Ahad A., Khar R.K., Jaggi M., Aqil M., Iqbal Z., Ahmad F.J., Talegaonkar S. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin. Ther. Patents 2011, 21:561-576.
4. Horton J.K., Thimmaiah K.N., Houghton J.A., Horowitz M.E., Houghton P.J. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem. Pharmacol. 1989, 38:1727-1736.
5. Sridhar R., Dwivedi C., Anderson J., Baker P.B., Sharma H.M., Desai P., Engineer F.N. Effects of verapamil on the acute toxicity of doxorubicin in vivo. J. Natl. Cancer Inst. 1992, 84:1653-1660.
6. Bertrand Y., Capdeville R., Balduck N., Philippe N. Cyclosporin A used to reverse drug resistance increases vincristine neurotoxicity. Am. J. Hematol. 1992, 40:158-159.
7. Negi L.M., Jaggi M., Talegaonkar S. Addressing the potential toxicities of the non-specific P-glycoprotein modulation by amalgamation with targeted approach in MDR tumors. Med. Hypotheses 2014, 82:240-242.
8. Goodison S., Urquidi V., Tarin D. CD44 cell adhesion molecules. Mol. Pathol. 1999, 52:189-196.
9. Negi L.M., Talegaonkar S., Jaggi M., Ahmad F.J., Iqbal Z., Khar R.K. Role of CD44 in tumour progression and strategies for targeting. J. Drug Target. 2012, 20:561-573.
10. Negi L.M., Jaggi M., Talegaonkar S. A logical approach to optimize the nanostructured lipid carrier system of irinotecan: efficient hybrid design methodology. Nanotechnology 2013, 24:015104.
11. Negi L.M., Jaggi M., Talegaonkar S. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Int. J. Pharm. 2014, 461:403-410.
12. Kose G.T., Arica M.Y., Hasirci V. Low-molecular-weight heparin-conjugated liposomes with improved stability and hemocompatibility. Drug Deliv. 1998, 5:257-264.
13. Weber C., Coester C., Kreuter J., Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int. J. Pharm. 2000, 194:91-102.
14. Kunjachan S., Gupta S., Dwivedi A.K., Dube A., Chourasia M.K. Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis. J. Microencapsul. 2011, 28:301-310.
15. Verma A.K., Sachin K. Novel hydrophilic drug polymer nano-conjugates of Cisplatin showing long blood retention profile: its release kinetics, cellular uptake and bio-distribution. Curr. Drug Deliv. 2008, 5:120-126.
16. Chuang T.W., Masters K.S. Regulation of polyurethane hemocompatibility and endothelialization by tethered hyaluronic acid oligosaccharides. Biomaterials 2009, 30:5341-5351.
17. Yu T., Malugin A., Ghandehari H. Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano 2011, 5:5717-5728.
18. Boone C., Sasaki M., McKee W. Characterization of an in vitro strain of Ehrlich-Lettre ascites carcinoma subjected to many periodic mouse passages. J. Natl. Cancer Inst. 1965, 34:725-740.
19. Chen L., Watkins J.F. Evidence against the presence of H2 histocompatibility antigens in Ehrlich ascites tumour cells. Nature 1970, 225:734-735.
20. Pessina A., Brambilla P., Mocarelli P. Surface antigen on Ehrlich ascites tumor cells. Biomedicine 1980, 33:105-109. [publiee pour l'A.A.I.C.I.G.].
21. Salem F.S., Badr M.O., Neamat-Allah A.N. Biochemical and pathological studies on the effects of levamisole and chlorambucil on Ehrlich ascites carcinoma-bearing mice. Vet. Ital. 2011, 47:89-95.
22. Upadhyay K.K., Mishra A.K., Chuttani K., Kaul A., Schatz C., Le Meins J.-F., Misra A., Lecommandoux S. The in vivo behavior and antitumor activity of doxorubicin-loaded poly (γ-benzyl l-glutamate)-block-hyaluronan polymersomes in Ehrlich ascites tumor-bearing BalB/c mice. Nanomedicine 2012, 8:71-80.
23. Verma A.K., Chanchal A., Chutani K. Augmentation of anti-tumour activity of cisplatin by pectin nano-conjugates in B-16 mouse model: pharmacokinetics and in-vivo biodistribution of radio-labelled, hydrophilic nano-conjugates. Int. J. Nanotechnol. 2012, 9:872-886.
24. Carrstensen H., Müller R.H., Müller B. Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake. Clin. Nutr. 1992, 11:289-297.
25. Richter W. Non-immunogenicity of purified hyaluronic acid preparations tested by passive cutaneous anaphylaxis. Int. Arch. Allergy Immunol. 1974, 47:211-217.
26. Dvash R., Khatchatouriants A., Solmesky L.J., Wibroe P.P., Weil M., Moghimi S.M., Peer D. Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes. J. Control. Release 2013, 170:295-305.
27. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
28. Avitabile T., Marano F., Castiglione F., Bucolo C., Cro M., Ambrosio L., Ferrauto C., Reibaldi A. Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits. Biomaterials 2001, 22:195-200.
29. Lee J.Y., Spicer A.P. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr. Opin. Cell Biol. 2000, 12:581-586.